The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
 
Jian-Ming Xu
No Relationships to Disclose
 
Rongrui Liu
No Relationships to Disclose
 
Yi Ba
No Relationships to Disclose
 
Da Jiang
No Relationships to Disclose
 
Mingxia Wang
No Relationships to Disclose
 
Yulong Zheng
No Relationships to Disclose
 
Jia Wei
No Relationships to Disclose
 
Yu-Xian Bai
No Relationships to Disclose
 
Lizhu Lin
No Relationships to Disclose
 
Jianping Xiong
No Relationships to Disclose
 
Xixi Zhu
No Relationships to Disclose
 
Chuanhua Zhao
No Relationships to Disclose
 
Ru Jia
No Relationships to Disclose
 
Yun Zhang
No Relationships to Disclose
 
Jianzhi Liu
No Relationships to Disclose
 
Gairong Zhang
No Relationships to Disclose
 
Guangze Li
No Relationships to Disclose
 
Quanren Wang
No Relationships to Disclose